To include your compound in the COVID-19 Resource Center, submit it here.

APF530 regulatory update

A.P. Pharma said it plans to resubmit an NDA for APF530 to prevent chemotherapy-induced nausea and vomiting (CINV) in 1H12 following a March meeting with FDA

Read the full 267 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE